(MedPage Today) — SEATTLE — Treating osteogenesis imperfecta with the parathyroid hormone teriparatide followed by zoledronic acid, a bisphosphonate, failed to reduce the risk of fractures compared with standard treatment, initial results of…
Source link : https://www.medpagetoday.com/meetingcoverage/asbmr/117377
Author :
Publish date : 2025-09-09 18:15:00
Copyright for syndicated content belongs to the linked Source.
